InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
63,054.61
(
-1.31%
)
Post# of 251715
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Gbathat

Send PM Follow Ignore
Followers 14
Posts 1305
Boards Moderated 0
Alias Born 06/05/2007

Gbathat

Re: None

Monday, 06/07/2021 2:01:02 PM

Monday, June 07, 2021 2:01:02 PM

Post# of 251715
$ARFXF on fire after biogen news

still a long way to run

ProMIS Neurosciences makes a more selective and specific antibody than Biogen's aducanumab. Aducanumab is limited by brain swelling effects but has shown some clinical benefit, hence FDA approval today and a boost in their market cap by about $10-15 BILLION in just an hour.

ARFXF (ProMIS) makes PMN310 which can be dosed at higher levels. The company has been pre-phase I for a while, and shareholders were told that PHI funding was contingent on FDA approval of aducanumab.

Here's the real kicker... PMN's market cap is only $60M... which is peanuts compared to the market opportunity.

$ARFXF

glta

God grant me the serenity to deal with the things I cannot change; courage to change the things I can and should; and wisdom to know the difference.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up